Dr. Fabian is a new investigator who shares laboratory facilities with our group at the Jewish General Hospital- Lady Davis Institute for Medical Research. His past work provided significant insights into microRNA function and regulation, and his current research extends his expertise to improving our understanding of microRNAs to explore new pathways for cancer treatment. We collaborate closely with his team to study the impact of DICER1 mutations on microRNA profiles and function.
Dr. Huang is a biochemist working on McGill campus whose research method uses functional genomic tools to study cancer-related pathways and to guide cancer therapies. His work includes high impact discoveries using shRNA screens to study drug resistance in cancer. He is a co-investigator on projects that aim to identify the pathways through which mutations in SMARCA4 lead to development of small cell carcinoma of the ovary at the molecular level with the ultimate goal of discovering druggable targets that can be used to improve treatment of the disease.
Dr. Majewski’s team specializes in the analysis of big genomics datasets. They collaborate with a number of basic researchers and clinicians at McGill and elsewhere. They contributed to most of our projects by applying their expertise to the bioinformatics analyses of our next generation sequencing data, including the development of new, specialized analytic tools to answer specific biological questions. Since most of our current projects include some big data components, Dr. Majewski’s assistance has proven invaluable to the success of our research program as a whole.
Dr. Witcher’s laboratory is also based at the Jewish General Hospital- Lady Davis Institute for Medical Research. His past and present work focuses on exploring the role of key epigenetic regulatory proteins in tumour initiation and development through activation of tumour suppressors, coordinating DNA repair and maintaining genome integrity. He collaborates with us to elucidate how mutations in SMARCA4, whose gene product is a component of the SWI-SNF chromatin-remodeling complex, lead to tumour development.
Dr. Jabado’s research laboratory is located next door to ours at the RIMUHC Glen site. Dr. Jabado’s research focuses on neurological tumours in children. Her group and ours share an interest in identifying predisposing genetic factors to tumour development. We collaborated closely on a project that identified predisposing FGFR1 mutations in familial and sporadic DNETs, with post-doctoral fellow Dr. Rivera from our group sharing her time between both labs to perform the necessary molecular characterisation of these benign developmental brain tumours.
Dr. Priest is a retired medical oncologist who brought profound expertise in the study and treatment of the childhood lung tumours known as pleuropulmonary blastoma, the most common malignant manifestation of the DICER1 tumour syndrome, to our research efforts. He was instrumental in helping us establish our DICER1 research program through his ties to The International Pleuropulmonary Blastoma Registry based in Minneapolis and by providing critical insight that helped define the DICER1 pleiotropic tumour syndrome phenotype.
Dr. Narod is a long-time collaborator and a world-leader in the field of breast and ovarian cancer genetics research. He studies various aspects of cancer prevention and screening and has participated in a large number of international studies in this field, including several joint studies with our group, among which is the recent discovery of the new breast cancer susceptibility gene, RECQL.
Dr. Tischkowitz’s research group shared a laboratory with our team for six years at the Lady Davis Institute before he established himself in the department of Medical Genetics at Cambridge University. Our joint research efforts have largely focused on better defining the role of the Fanconi Anemia gene PALB2 as a breast cancer susceptibility gene, including the discovery and characterization of a Founder mutation in the Quebec population. He has been a driving force in the establishment of the PALB2 Interest Group, a research consortium that includes over 100 members who are clinicians, epidemiologist and researchers from around the world, all working on PALB2.
Dr. Malkin is active in clinical oncology practice as well as in research. He specializes in the genetics of childhood cancers and is an active collaborator on our DICER1 project and he has referred a numbers of patients identified in his clinical practice to our research program. We recently secured joint funding to establish a pan-Canadian DICER1 Network to enable the identification of DICER1 mutation carriers from pediatric medical centers Canada wide, and we collaborate on a new project to develop an app to guide pediatric physicians in making decisions with regards to referral of their patients to genetic services.
Dr. Reis-Filho is a surgical pathologist whose research focus is on rare types of breast cancer. He has experience in breast cancer gene expression profiling and genomics and combines traditional pathology information with data generated with high-throughput molecular techniques to investigate breast tumours at the genetic level. He has been lending his expertise to our molecular characterization of breast tumours from PALB2 mutation carriers.
Dr. Clarke is a gynecological pathologist with a strong interest in molecular characterisation. He uses his expertise with molecular pathology techniques to study gynecological tumours, common and rare. He was of great assistance to us for our SMARCA4 project and continues to assist with any other project where gynecological tumours play a role.
Dr. Dal Soglio is a pathologist at the Ste-Justine hospital for children who has helped us bridge the two major university affiliated medical networks in Montreal. For many years she has been a steadfast collaborator who helped with procuring samples as well as with review, dissection and documentation of large numbers of tumours retrieved from hospital archives to assist in our molecular genetics studies. She provided especially critical expertise with the early characterization of DICER1-related tumours such as Sertoli-Leydig cell tumours and DICER1-related Wilms tumours that helped us confirm these tumours as established features of the syndrome. Recently, she helped us define the pathological, molecular and genetic similarities and differences between DICER1 mutation carriers and carriers of PTEN mutations.
Dr. Albrecht’s expertise as a neuropathologist has been instrumental in characterizing a large number of tumour samples in both our DICER1, SCCOHT and DNET projects.
Dr. McCluggage is a Gynaecological Pathologist who specializes in the study of cellular pathology. His contributions have been of great importance for our research in SCCOHT and SMARCA4 genes. Dr. McCluggage is very active referring us patients for our studies as well as other interesting gynecological pathology cases.
Dr. Hasselblat is a neuropathologist who has an interest in rhabdoid tumors. Our collaboration goes back to the year 2013. Dr. Hasselblat has helped us with the staining when researching SMARCA4 and SCCOHT projects.
Dr. Niedziela is a very important collaborator on our DICER1 research. He routinely sends us interesting cases for our study. Dr Niedziela is also always open to discuss cases and share his thoughts as an expert pediatric endocrinologist.
Dr. Foulkes' team and Catherine collaborate in the development of a Cancer Genetics Referral Guideline which will take the form of an electronic tool, called the McGill Interactive Pediatric OncoGenetic Guideline. Catherine has collaborated in the past by helping our research on small cell carcinoma of the ovary-hypercalcemic type (SCCOHT). She's still involved with the lab helping Leanne de Kock and Mona Wu on various DICER initiatives.
Dr. Orthwein collaborates often with Dr. Rivera in our RAD51D research. As a world renowned expert in DNA repair he helps us functionally characterize mutations in DNA repair genes found in breast and ovarian cancer patients.